Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B??, Current Biology, vol.7, issue.4, pp.261-269, 1997. ,
DOI : 10.1016/S0960-9822(06)00122-9
Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study, Investigational New Drugs, vol.30, issue.3, pp.677-684, 2013. ,
DOI : 10.1007/s10637-012-9860-4
AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K, Oncogene, vol.159, issue.1, pp.150-155, 2010. ,
DOI : 10.1002/1097-0215(20001115)88:4<620::AID-IJC16>3.0.CO;2-Z
Somatic mutation of PTEN in bladder carcinoma, British Journal of Cancer, vol.80, issue.5/6, pp.904-908, 1999. ,
DOI : 10.1038/sj.bjc.6690439
Clinical model of lifetime cost of treating bladder cancer and associated complications, Urology, vol.68, pp.549-553, 2006. ,
EAU guidelines on, Palou Redorta, J., & Roupret, M, 2013. ,
Actionable mutations in muscle-invasive bladder cancer, Current Opinion in Urology, vol.23, issue.5, 2013. ,
DOI : 10.1097/MOU.0b013e328363a3cd
Systemic chemotherapy in inoperable or metastatic bladder cancer, Annals of Oncology, vol.17, issue.4, pp.553-561, 2005. ,
DOI : 10.1093/annonc/mdj079
Targeting the PI3K signaling pathway in cancer therapy, Expert Opinion on Therapeutic Targets, vol.56, issue.6, pp.121-130, 2012. ,
DOI : 10.1158/0008-5472.CAN-04-1399
The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma, Experimental Cell Research, vol.315, issue.3, pp.485-497, 1027. ,
DOI : 10.1016/j.yexcr.2008.11.007
The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro, Urol Oncol, pp.251-00252, 2013. ,
Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy, Ann Oncol, vol.24, pp.1466-1472, 2013. ,
Rapamycin passes the torch: a new generation of mTOR inhibitors, Nature Reviews Drug Discovery, vol.10, issue.11, pp.868-880, 2011. ,
DOI : 10.1038/nrd3531
Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response, European Journal of Cancer (1965), vol.8, issue.6, 1972. ,
DOI : 10.1016/0014-2964(72)90137-5
Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin, Mol Cancer Ther, vol.10, pp.1394-1406, 2011. ,
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer, Endocrine Related Cancer, vol.20, issue.3, pp.12-0394, 2013. ,
DOI : 10.1530/ERC-12-0394
The impact of variant histology on the outcome of bladder cancer treated with curative intent, Urologic Oncology: Seminars and Original Investigations, vol.27, issue.1, 1014. ,
DOI : 10.1016/j.urolonc.2007.07.010
A novel N-terminal hydrophobic motif mediates constitutive degradation of serum- and glucocorticoid-induced kinase-1 by the ubiquitin-proteasome pathway, FEBS Journal, vol.10, issue.1, pp.2913-2928, 2006. ,
DOI : 10.1083/jcb.200201053
OSU-03012 interacts with lapatinib to kill brain cancer cells, Cancer Biology & Therapy, vol.15, issue.14, pp.1501-1511, 2012. ,
DOI : 10.2174/156800911797264743
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours, British Journal of Cancer, vol.18, issue.5, pp.1085-1092, 2013. ,
DOI : 10.1186/bcr2883
PI3K and mTOR inhibitors???a new generation of targeted anticancer agents, Current Opinion in Cell Biology, vol.21, issue.2, 1017. ,
DOI : 10.1016/j.ceb.2008.12.011
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer, Invest New Drugs, p.7, 2014. ,
Epidemiology and Risk Factors of Urothelial Bladder Cancer, European Urology, vol.63, issue.2, pp.234-241, 2013. ,
DOI : 10.1016/j.eururo.2012.07.033
First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors., Journal of Clinical Oncology, vol.28, issue.15_suppl, 2010. ,
DOI : 10.1200/jco.2010.28.15_suppl.3005
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway, Cancer Chemotherapy and Pharmacology, vol.81, issue.Suppl 3, pp.829-842, 2013. ,
DOI : 10.1007/s00280-012-2043-3
Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers, Oncogene, vol.16, issue.24, pp.3215-3218, 1998. ,
DOI : 10.1038/sj.onc.1201855
The Phosphoinositide 3-Kinase Pathway, Science, vol.296, issue.5573, pp.1655-1657, 2002. ,
DOI : 10.1126/science.296.5573.1655
Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder, Oncogene, vol.14, issue.25, 1997. ,
DOI : 10.1038/sj.onc.1201154
Critical roles for mTORC2-and rapamycininsensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells, Proc Natl Acad Sci, vol.107, pp.12469-12474, 2010. ,
Mechanisms of mTOR inhibitor resistance in cancer therapy, Targeted Oncology, vol.24, issue.1, pp.17-27, 2011. ,
DOI : 10.1007/s11523-011-0167-8
Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit, J Biol Chem, vol.268, pp.9478-9483, 1993. ,
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer, Nature, vol.448, pp.439-444, 2004. ,
Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors, Cell Cycle, vol.7, issue.24, pp.3805-3809, 2008. ,
DOI : 10.4161/cc.7.24.7244
PTEN and the PI3-Kinase Pathway in Cancer, Annual Review of Pathology: Mechanisms of Disease, vol.4, issue.1, pp.127-50, 2009. ,
DOI : 10.1146/annurev.pathol.4.110807.092311
Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy, Leukemia, vol.17, issue.3, pp.590-603, 2003. ,
DOI : 10.1038/sj.leu.2402824
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas, J Clin Oncol, vol.30, pp.78-84, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-01058262
Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway, Laboratory Investigation, vol.6, issue.10, pp.1406-1414, 2010. ,
DOI : 10.1016/j.radonc.2006.07.032
Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells, Clinical Cancer Research, vol.17, issue.9, pp.2863-2873, 2011. ,
DOI : 10.1158/1078-0432.CCR-09-3202
The PI3K Pathway As Drug Target in Human Cancer, Journal of Clinical Oncology, vol.28, issue.6, pp.1075-1083, 2010. ,
DOI : 10.1200/JCO.2009.25.3641
The Tuberous Sclerosis Complex, New England Journal of Medicine, vol.355, issue.13, pp.1345-1356, 2006. ,
DOI : 10.1056/NEJMra055323
Aktdependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK, 2008. ,
In search of antiaging modalities: Evaluation of mTOR- and ROS/DNA damage-signaling by cytometry, Cytometry Part A, vol.221, issue.5, 2014. ,
DOI : 10.1002/cyto.a.22452
Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background, Mol Cancer Ther, vol.11, pp.873-887, 2012. ,
An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo, Cancer Chemother Pharmacol, vol.71, pp.867-881, 2013. ,
CREB Is a Regulatory Target for the Protein Kinase Akt/PKB, Journal of Biological Chemistry, vol.273, issue.49, pp.32377-32379, 1998. ,
DOI : 10.1074/jbc.273.49.32377
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors, Mol Carcinog, p.22125, 2013. ,
The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR, Autophagy, vol.7, issue.6, pp.643-644, 2011. ,
DOI : 10.4161/auto.7.6.15123
Targeting PI3K signalling in cancer: opportunities, challenges and limitations, Nature Reviews Cancer, vol.16, issue.8, 2009. ,
DOI : 10.1038/nrc2664
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism, Nature Reviews Genetics, vol.61, issue.8, pp.606-619, 2006. ,
DOI : 10.1073/pnas.84.14.5034
Impact of gender on bladder cancer incidence, staging, and prognosis, World Journal of Urology, vol.185, issue.4, pp.457-463, 2011. ,
DOI : 10.1007/s00345-011-0709-9
Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors, Cancer Res, vol.71, pp.1573-1583, 2011. ,
Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Advanced Lung Neuroendocrine Tumors, Chest, vol.143, issue.4, pp.955-962, 2013. ,
DOI : 10.1378/chest.12-1108
Rapamycin Inhibits In Vitro Growth and Release of Angiogenetic Factors in Human Bladder Cancer, Urology, vol.73, issue.3, pp.665-668, 2009. ,
DOI : 10.1016/j.urology.2008.09.070
Everolimus for astrocytomas in tuberous sclerosis ??? Author's reply, The Lancet, vol.381, issue.9874, pp.60837-60835, 2013. ,
DOI : 10.1016/S0140-6736(13)60837-5
mSin1 Is Necessary for Akt/PKB Phosphorylation, and Its Isoforms Define Three Distinct mTORC2s, Current Biology, vol.16, issue.18, pp.1865-1870, 1817. ,
DOI : 10.1016/j.cub.2006.08.001
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation, Bioorganic & Medicinal Chemistry Letters, vol.23, issue.13, 2013. ,
DOI : 10.1016/j.bmcl.2013.05.007
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia, N Engl J Med, vol.370, pp.997-1007, 2014. ,
PHLPP: a phosphatase that directly dephosphorylates, 2005. ,
mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1), Biochemical Journal, vol.416, issue.3, 2008. ,
DOI : 10.1042/BJ20081668
URL : https://hal.archives-ouvertes.fr/hal-00479087
A phase II trial of temsirolimus in second-line metastatic urothelial cancer, Med Oncol, vol.29, pp.2870-2876, 2012. ,
Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium, Urologic Oncology: Seminars and Original Investigations, vol.28, issue.4, pp.409-428, 2010. ,
DOI : 10.1016/j.urolonc.2010.04.003
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study, J Clin Oncol, vol.29, pp.4320-4326, 2011. ,
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder, Nature Genetics, vol.63, issue.9, pp.875-878, 2011. ,
DOI : 10.1038/nature07423
involvement in bladder cancer: diverse effects and??therapeutic implications, The Journal of Pathology, vol.2, issue.1, pp.17-27, 2013. ,
DOI : 10.1002/path.4176
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action, Cell, vol.110, pp.177-189, 2002. ,
The TSC1-2 tumor suppressor controls insulin???PI3K signaling via regulation of IRS proteins, The Journal of Cell Biology, vol.65, issue.2, pp.213-223, 2004. ,
DOI : 10.1038/ncb999
The Akt-mTOR tango and its relevance to cancer, Cancer Cell, vol.8, issue.3, pp.179-183, 2005. ,
DOI : 10.1016/j.ccr.2005.08.008
Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor, Bioorganic & Medicinal Chemistry Letters, vol.20, issue.8, pp.2408-2411, 2010. ,
DOI : 10.1016/j.bmcl.2010.03.046
Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast, Science, vol.253, issue.5022, pp.905-909, 1991. ,
DOI : 10.1126/science.1715094
Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor, Blood, vol.116, issue.22, pp.4560-4568, 2010. ,
DOI : 10.1182/blood-2010-05-285726
Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014, Biochemical and Biophysical Research Communications, vol.443, issue.2, pp.406-412, 2014. ,
DOI : 10.1016/j.bbrc.2013.11.099
Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.32, issue.8, pp.760-767, 2014. ,
DOI : 10.1200/JCO.2013.50.3961
Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling, Mol Cancer Ther, vol.3, pp.763-772, 2004. ,
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling, Genes & Development, vol.17, issue.15, pp.1829-1834, 1817. ,
DOI : 10.1101/gad.1110003
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling, Nature Cell Biology, vol.4, issue.9, pp.648-657, 2002. ,
DOI : 10.1038/ncb839
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival, Cell, vol.115, issue.5, pp.577-590, 2003. ,
DOI : 10.1016/S0092-8674(03)00929-2
Genome Sequencing Identifies a Basis for Everolimus Sensitivity, Science, vol.338, issue.6104, p.221, 2012. ,
DOI : 10.1126/science.1226344
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive, Nature Cell Biology, vol.59, issue.11, pp.1122-1128, 1123. ,
DOI : 10.1006/jmbi.2000.4042
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial, Lancet Oncol, vol.13, pp.549-558, 2012. ,
Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder, Cancer Res, vol.48, pp.3853-3855, 1988. ,
Cellular Function of Phosphoinositide 3-Kinases: Implications for Development, Immunity, Homeostasis, and Cancer, Annual Review of Cell and Developmental Biology, vol.17, issue.1, pp.615-675, 2001. ,
DOI : 10.1146/annurev.cellbio.17.1.615
mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery, Cell, vol.110, issue.2, pp.163-175, 2002. ,
DOI : 10.1016/S0092-8674(02)00808-5
G??L, a Positive Regulator of the Rapamycin-Sensitive Pathway Required for the Nutrient-Sensitive Interaction between Raptor and mTOR, Molecular Cell, vol.11, issue.4, pp.895-904, 2003. ,
DOI : 10.1016/S1097-2765(03)00114-X
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1, Nature Cell Biology, vol.4, issue.2, pp.132-141, 2011. ,
DOI : 10.1016/j.cub.2010.04.041
Recent Advances in Treatment of Advanced Urothelial Carcinoma, Current Urology Reports, vol.18, issue.3, pp.147-152, 2012. ,
DOI : 10.1007/s11934-012-0238-0
A Pharmacological Map of the PI3-K Family Defines a Role for p110?? in Insulin Signaling, Cell, vol.125, issue.4, pp.733-747, 2006. ,
DOI : 10.1016/j.cell.2006.03.035
Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder, Cancer Res, vol.63, pp.7652-7656, 2003. ,
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer, Cancer and Metastasis Reviews, vol.25, issue.23, pp.305-316, 2009. ,
DOI : 10.1007/s10555-009-9198-3
A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma, BJU International, vol.281, issue.11c, p.29, 2012. ,
DOI : 10.1111/j.1464-410X.2012.11569.x
Perifosine ??? a new option in treatment of acute myeloid leukemia?, Expert Opinion on Investigational Drugs, vol.30, issue.21, pp.1315-1327, 2013. ,
DOI : 10.1038/nrd2926
Rapalogs and mTOR inhibitors as anti-aging therapeutics, Journal of Clinical Investigation, vol.123, issue.3, pp.980-989, 2013. ,
DOI : 10.1172/JCI64099
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582126
PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest, Nature Medicine, vol.9, issue.10, pp.1153-1160, 1116. ,
DOI : 10.1016/0092-8674(95)90534-0
Systemic therapy for metastatic urothelial carcinoma, BJU International, vol.23, issue.7, pp.795-803, 2005. ,
DOI : 10.1634/theoncologist.10-8-565
Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models, Clinical Cancer Research, vol.19, issue.7, pp.1760-1772, 2013. ,
DOI : 10.1158/1078-0432.CCR-12-3072
Integrated Genomic and Gene Expression Profiling Identifies Two Major Genomic Circuits in Urothelial Carcinoma, PLoS ONE, vol.21, issue.6, p.38863, 2012. ,
DOI : 10.1371/journal.pone.0038863.s008
Targeting the phosphoinositide 3-kinase pathway in cancer, Nature Reviews Drug Discovery, vol.3, issue.8, pp.627-644, 1038. ,
DOI : 10.1038/nrd2926
Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR, Cancer Research, vol.73, issue.8, pp.2574-2586, 2013. ,
DOI : 10.1158/0008-5472.CAN-12-1702
Akt Inhibitor A-443654 Interferes with Mitotic Progression by Regulating Aurora A Kinase Expression, Neoplasia, vol.10, issue.8, pp.828-837, 2008. ,
DOI : 10.1593/neo.08408
PIK3CA Mutations Are an Early Genetic Alteration Associated with FGFR3 Mutations in Superficial Papillary Bladder Tumors, Cancer Research, vol.66, issue.15, pp.7401-7404, 2006. ,
DOI : 10.1158/0008-5472.CAN-06-1182
Phosphorylation and Functional Inactivation of TSC2 by Erk, Cell, vol.121, issue.2, pp.179-193, 2005. ,
DOI : 10.1016/j.cell.2005.02.031
Identification and characterization of, 2012. ,
Antitumor Efficacy Profile of PKI-402, a Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor, Molecular Cancer Therapeutics, vol.9, issue.4, pp.976-984, 2010. ,
DOI : 10.1158/1535-7163.MCT-09-0954
NVP-BEZ235 as a New Therapeutic Option for Sarcomas, Clinical Cancer Research, vol.16, issue.2, pp.530-540, 2010. ,
DOI : 10.1158/1078-0432.CCR-09-0816
Rheb fills a GAP between TSC and TOR, Trends in Biochemical Sciences, vol.28, issue.11, pp.573-576, 2003. ,
DOI : 10.1016/j.tibs.2003.09.003
Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer, Cancer Biology & Therapy, vol.8, issue.24, 2009. ,
DOI : 10.4161/cbt.8.24.9987
Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction, Cancer Epidemiol Biomarkers Prev, vol.9, pp.461-467, 2000. ,
NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case???control studies conducted in the general population, Pharmacogenetics, vol.10, issue.2, pp.115-122, 2000. ,
DOI : 10.1097/00008571-200003000-00003
Targeting the PI3K/Akt/mTOR Pathway ??? Beyond Rapalogs, Oncotarget, vol.1, issue.7, pp.530-543, 2010. ,
DOI : 10.18632/oncotarget.188
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors, Annals of Oncology, vol.23, issue.9, pp.2399-2408, 2012. ,
DOI : 10.1093/annonc/mds011
Hsp70 associates with Rictor and is required for mTORC2 formation and activity, Biochemical and Biophysical Research Communications, vol.372, issue.4, pp.578-583, 2008. ,
DOI : 10.1016/j.bbrc.2008.05.086
GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study, 2013. ,
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance, Oncotarget, vol.3, pp.1068-1111, 2012. ,
Akt/mTOR cascades which alter therapy response, Oncotarget, vol.3, pp.954-987 ,
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation, Trends in Biochemical Sciences, vol.36, issue.6, pp.320-328, 2011. ,
DOI : 10.1016/j.tibs.2011.03.006
Genetic alterations in urothelial bladder carcinoma, Cancer, vol.64, issue.Suppl C, pp.1205-1216, 2006. ,
DOI : 10.1002/cncr.21743
Phase II study of everolimus in metastatic urothelial cancer, BJU Int, vol.112, pp.462-470, 2013. ,
Phase 3 trial of everolimus for metastatic renal cell carcinoma, Cancer, vol.356, issue.suppl, pp.4256-4265, 2010. ,
DOI : 10.1002/cncr.25219
Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1, Biochemical Journal, vol.62, issue.2, pp.357-369, 2011. ,
DOI : 10.1101/gad.1775409
mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through??AMBRA1 and TRAF6, Nature Cell Biology, vol.3, issue.4, pp.406-416, 2013. ,
DOI : 10.1016/S0896-6273(00)81031-4
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR, Proc Natl Acad Sci U S A, vol.98, pp.10314-10319, 2001. ,
Comprehensive molecular characterization of urothelial bladder carcinoma, Nature, 2014. ,
mTOR complex 2 signaling and functions, Cell Cycle, vol.2, issue.14, pp.2305-2316, 2011. ,
DOI : 10.1016/j.tibs.2011.03.006
mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide, The EMBO Journal, vol.15, issue.23, pp.3939-3951, 2010. ,
DOI : 10.1158/0008-5472.CAN-09-0299
Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study, Journal of Clinical Oncology, vol.31, issue.31, pp.3935-3943, 2013. ,
DOI : 10.1200/JCO.2012.48.3552
Effect of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine, Urological Research, vol.3, issue.2, 1975. ,
DOI : 10.1007/BF00256185
NFkappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase, Nature, vol.401, issue.6748, pp.82-85, 1999. ,
DOI : 10.1038/43466
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study, The Lancet, vol.378, issue.9808, pp.2005-2012, 2011. ,
DOI : 10.1016/S0140-6736(11)61742-X
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival, Cell, vol.137, pp.873-886, 1014. ,
Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014, Bioorganic & Medicinal Chemistry Letters, vol.23, issue.5, pp.1212-1216, 2013. ,
DOI : 10.1016/j.bmcl.2013.01.019
The present and future burden of urinary bladder cancer in the world, World Journal of Urology, vol.102, issue.2, pp.289-293, 2009. ,
DOI : 10.1007/s00345-009-0383-3
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/-mice, Proc Natl Acad Sci U S A, vol.98, pp.10320-10325, 2001. ,
The Met receptor tyrosine kinase and basal breast cancer, Cell Cycle, vol.9, issue.6, pp.1043-1050, 2010. ,
DOI : 10.4161/cc.9.6.11033
The mTOR Signalling Pathway in Human Cancer, International Journal of Molecular Sciences, vol.13, issue.12, 2012. ,
DOI : 10.3390/ijms13021886
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide, Neuro-Oncology, vol.13, issue.4, pp.384-392, 2011. ,
DOI : 10.1093/neuonc/noq193
Detection of chromosomal imbalances in papillary bladder tumors by comparative genomic hybridization, Urology, vol.57, issue.5, pp.986-992, 2001. ,
DOI : 10.1016/S0090-4295(01)00909-8
Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity, Cancer Res, vol.68, pp.5915-5923, 2008. ,
Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms, Human Molecular Genetics, vol.17, issue.13, pp.2006-2017, 2007. ,
DOI : 10.1093/hmg/ddn098
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases, Cancer Res, vol.67, pp.5840-5850, 2007. ,
Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity, Cancer Research, vol.68, issue.7, pp.2366-2374, 1158. ,
DOI : 10.1158/0008-5472.CAN-07-5783
Chromosomal imbalances are associated with a high risk of progression in early invasive (pT1) urinary bladder cancer, Cancer Res, vol.59, pp.5687-5691, 1999. ,
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors, Investigational New Drugs, vol.9, issue.8, p.21, 2014. ,
DOI : 10.1007/s10637-014-0082-9
Development of PI3K inhibitors: lessons learned from early clinical trials, Nature Reviews Clinical Oncology, vol.72, issue.3, pp.143-153, 2013. ,
DOI : 10.1038/nrclinonc.2013.10
PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs, Oncogene, vol.9, issue.6, pp.768-776, 2013. ,
DOI : 10.1002/elps.1150181505
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase, Mol Cell, vol.25, pp.903-915, 2007. ,
Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton, Current Biology, vol.14, issue.14, pp.1296-1302, 2004. ,
DOI : 10.1016/j.cub.2004.06.054
Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex, Science, vol.307, issue.5712, pp.1098-1101, 2005. ,
DOI : 10.1126/science.1106148
Specific activation of mTORC1 by Rheb Gprotein in vitro involves enhanced recruitment of its substrate protein, J Biol Chem, vol.284, 2009. ,
PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation, British Journal of Cancer, vol.62, issue.6, pp.1586-1592, 2013. ,
DOI : 10.1186/1471-2490-11-19
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers, Annals of Oncology, vol.23, issue.10, pp.2663-2670, 2012. ,
DOI : 10.1093/annonc/mds057
Functional and molecular characterization of kinin B1 and B2 receptors in human bladder cancer: implication of the PI3K?? pathway, Investigational New Drugs, vol.188, issue.4, pp.812-822, 2013. ,
DOI : 10.1007/s10637-012-9907-6
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors, Clinical Cancer Research, vol.20, issue.1, pp.233-245, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-1777
Ras, PI(3)K and mTOR signalling controls tumour cell growth, Nature, vol.12, issue.7092, pp.424-430, 2006. ,
DOI : 10.1038/nature04869
Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779, Cancer Res, vol.62, pp.5027-5034, 2002. ,
Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy, Proc Natl Acad Sci U S A, vol.105, 2008. ,
Effects of Isoform-selective Phosphatidylinositol 3-Kinase Inhibitors on Osteoclasts: ACTIONS ON CYTOSKELETAL ORGANIZATION, SURVIVAL, AND RESORPTION, Journal of Biological Chemistry, vol.288, issue.49, pp.35346-35357, 2013. ,
DOI : 10.1074/jbc.M113.507525
Patterns of chromosomal imbalances in muscle invasive bladder cancer., International Journal of Oncology, vol.17, pp.1025-1029, 2000. ,
DOI : 10.3892/ijo.17.5.1025
Chemotherapeutic and targeted biological agents for metastatic bladder cancer: A comprehensive review, International Journal of Urology, vol.41, issue.Suppl 1, p.12407, 2014. ,
DOI : 10.1111/iju.12407
A Systematic Study of Gene Mutations in Urothelial Carcinoma; Inactivating Mutations in TSC2 and PIK3R1, PLoS ONE, vol.28, issue.2, p.18583, 2011. ,
DOI : 10.1371/journal.pone.0018583.s004
FHIT gene expression in human urinary bladder transitional cell carcinomas, In Vivo, vol.15, pp.169-173, 2001. ,
Frequent truncating mutations of STAG2 in bladder cancer, Nat Genet, vol.45, pp.1428-1430, 2013. ,
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors, Oncogene, vol.27, pp.4086-4095, 2008. ,
Akt as a therapeutic target in cancer, Expert Opinion on Therapeutic Targets, vol.21, issue.9, 2008. ,
DOI : 10.1074/jbc.M403775200
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines, Eur Urol, vol.59, pp.1009-1018, 2011. ,
Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B, Science, vol.277, pp.567-570, 1997. ,
Analysis of 3-phosphoinositide-dependent kinase-1 signaling and function in ES cells, Experimental Cell Research, vol.314, issue.11-12, 2008. ,
DOI : 10.1016/j.yexcr.2008.04.006
First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1, patients with advanced solid tumors and lymphoma, 2010. ,
The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations, Clinical Cancer Research, vol.17, issue.10, pp.3272-3281, 2011. ,
DOI : 10.1158/1078-0432.CCR-10-2882
Multidrug resistance-associated protein 1, 2007. ,
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1, J Biol Chem, vol.284, 2009. ,
LKB1 mutations and their correlation with LKB1 and Rheb expression in bladder cancer, Molecular Carcinogenesis, vol.377, issue.8, pp.660-665, 2013. ,
DOI : 10.1002/mc.21902
Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study, Target Oncol, vol.8, pp.243-251, 2013. ,
PKI- 179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor, Bioorg Med Chem Lett, vol.20, pp.5869-5873, 2010. ,
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer, Journal of Clinical Oncology, vol.23, issue.21, pp.4602-4608, 2005. ,
DOI : 10.1200/JCO.2005.07.757
Molecular analysis ofPTEN andMXI1 in primary bladder carcinoma, International Journal of Cancer, vol.45, issue.4, pp.620-625, 2000. ,
DOI : 10.1002/1097-0215(20001115)88:4<620::AID-IJC16>3.0.CO;2-Z
OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2, BMC Cancer, vol.80, issue.5, pp.1471-2407, 2013. ,
DOI : 10.1158/0008-5472.CAN-05-3092
The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair, Oncogene, vol.27, issue.40, pp.3586-3596, 2009. ,
DOI : 10.1038/onc.2009.215
Oncogenic FGFR3 gene fusions in bladder cancer, Human Molecular Genetics, vol.22, issue.4, pp.795-803, 2013. ,
DOI : 10.1093/hmg/dds486
EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines, European Urology, vol.65, issue.4, pp.778-792, 2014. ,
DOI : 10.1016/j.eururo.2013.11.046
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer, J Clin Oncol, vol.31, pp.195-202, 2013. ,
Identification of targetable FGFR gene fusions in diverse cancers, Cancer Discov, vol.3, pp.636-647, 2013. ,
Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor, J Natl Cancer Inst, vol.98, pp.545-556, 2006. ,
mTOR kinase structure, mechanism and regulation, Nature, vol.276, issue.7448, pp.217-223, 2013. ,
DOI : 10.1107/S0907444909052925
Ethnic Differences in Bladder Cancer Survival, Urology, vol.78, issue.3, pp.544-549, 2011. ,
DOI : 10.1016/j.urology.2011.02.042
FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal, The Journal of Experimental Medicine, vol.203, issue.7, pp.1657-1663, 1626. ,
DOI : 10.4049/jimmunol.175.6.3790
Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2, Cancer Research, vol.70, issue.2, pp.621-631, 2010. ,
DOI : 10.1158/0008-5472.CAN-09-2340
Biochemical, cellular, and in vivo activity of novel ATPcompetitive and selective inhibitors of the mammalian target of rapamycin, Cancer Res, vol.69, 2009. ,
PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity, Mol Cancer Ther, vol.10, pp.2189-2199, 2011. ,
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML, Blood, vol.109, issue.8, pp.3509-3512, 2006. ,
DOI : 10.1182/blood-2006-06-030833
Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis, 2011. ,
DOI : 10.2174/9781681082332116030009
From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3- phosphoinositide-dependent protein kinase-1 inhibitors, Cancer Res, vol.64, pp.4309-4318, 2004. ,
mTOR: from growth signal integration to cancer, diabetes and ageing, Nature Reviews Molecular Cell Biology, vol.20, issue.1, pp.21-35, 2011. ,
DOI : 10.1038/nrm3025
The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells, Mol Med Rep, vol.5, pp.503-508, 2011. ,